A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
BeOne Medicines
Gilead Sciences
Hoffmann-La Roche
Arcus Biosciences, Inc.
Wake Forest University Health Sciences
ToLymph Inc.
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Intergroupe Francophone de Cancerologie Thoracique
ETOP IBCSG Partners Foundation
BeOne Medicines
Dana-Farber Cancer Institute
Swiss Cancer Institute
Fundación GECP
Sun Yat-sen University
University of Iowa
Università Vita-Salute San Raffaele
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Shanghai Hengrui Pharmaceutical Co., Ltd.
Mayo Clinic
Fundación GECP
Intergroupe Francophone de Cancerologie Thoracique
Washington University School of Medicine
Weill Medical College of Cornell University
Bristol-Myers Squibb
Duke University
NRG Oncology
Genfleet Therapeutics (Shanghai) Inc.
BeiGene
University of Alabama at Birmingham
Gustave Roussy, Cancer Campus, Grand Paris
Shanghai Junshi Bioscience Co., Ltd.
Iovance Biotherapeutics, Inc.
NanOlogy, LLC
Samsung Medical Center
Fundación GECP
Fox Chase Cancer Center
Merck Sharp & Dohme LLC
EpicentRx, Inc.
Boehringer Ingelheim
Latin American Cooperative Oncology Group
Tufts Medical Center
Spanish Lung Cancer Group
Xiangya Hospital of Central South University
Hunan Province Tumor Hospital
University of Iowa
Tang-Du Hospital
Puma Biotechnology, Inc.
Sun Yat-sen University